Literature DB >> 18238985

Endometrial cancer.

Joel I Sorosky1.   

Abstract

This review summarizes the epidemiology, prevention, diagnosis and treatment, and prognosis of endometrial carcinoma. Although the incidence of disease has remained stable, the death rate has increased over 100% over the last two decades. Precursor lesions of complex hyperplasia with atypia are associated with an endometrial carcinoma in over 40% of cases. The percentage of obese women with endometrial cancer is increasing. The incidence of endometrial cancer in white women is twice the incidence in African-American women, but stage for stage, African-American women have a less favorable prognosis. Preoperative imaging cannot accurately assess lymph node involvement. Gross examination of depth of myometrial invasion does not have the sensitivity, specificity, and positive or negative predictive value to select women who can have lymphadenectomy safely omitted from the surgical procedure. In the absence of ideal noninvasive preoperative testing, surgical staging remains the most accurate method of determining the extent of disease. There has been an increase in surgical staging and a decrease in postoperative adjuvant pelvic radiation therapy over the past two decades. Women with a family history of hereditary nonpolyposis colorectal colon cancer are at increased risk for endometrial cancer. Conservative treatment to allow for childbearing is possible in select situations. Women with endometrial cancer should be managed by physicians experienced in the treatment of this disease.

Entities:  

Mesh:

Year:  2008        PMID: 18238985     DOI: 10.1097/AOG.0b013e318162f690

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  56 in total

1.  Comparison of laparoscopic versus conventional open surgical staging procedure for endometrial cancer.

Authors:  Tae Wook Kong; Kyung Mi Lee; Ji Yoon Cheong; Woo Young Kim; Suk-Joon Chang; Seung-Chul Yoo; Jong-Hyuck Yoon; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

2.  Significant association between IL-32 gene polymorphisms and susceptibility to endometrial cancer in Chinese Han women.

Authors:  Xiuzhang Yu; Bin Zhou; Zhu Zhang; Qianqian Gao; Yanyun Wang; Yaping Song; Yan Pu; Yue Chen; Ruiqi Duan; Lin Zhang; Mingrong Xi
Journal:  Tumour Biol       Date:  2015-02-09

3.  The activity of class I, II, III, and IV alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in endometrial cancer.

Authors:  Karolina Orywal; Wojciech Jelski; Michał Zdrodowski; Maciej Szmitkowski
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

4.  Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging.

Authors:  K Kinkel; R Forstner; F M Danza; L Oleaga; T M Cunha; A Bergman; J O Barentsz; C Balleyguier; B Brkljacic; J A Spencer
Journal:  Eur Radiol       Date:  2009-02-05       Impact factor: 5.315

5.  Robotic surgery compared with laparotomy for high-grade endometrial cancer.

Authors:  Alok Pant; Julian Schink; John Lurain
Journal:  J Robot Surg       Date:  2014-01-12

Review 6.  FDG-PET in gynaecological cancers: recent observations.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11       Impact factor: 9.236

7.  Evaluation of COMT Gene rs4680 Polymorphism as a Risk Factor for Endometrial Cancer.

Authors:  Pradeep Kumar; Garima Singh; Vandana Rai
Journal:  Indian J Clin Biochem       Date:  2018-12-04

8.  Clinical analysis of endometrial cancer patients with obesity, diabetes, and hypertension.

Authors:  Xiang-Hua Yin; Hong-Yan Jia; Xiao-Rui Xue; Shi-Zhang Yang; Zhong-Qin Wang
Journal:  Int J Clin Exp Med       Date:  2014-03-15

9.  Controversies in surgical staging of endometrial cancer.

Authors:  R Seracchioli; S Solfrini; M Mabrouk; C Facchini; N Di Donato; L Manuzzi; L Savelli; S Venturoli
Journal:  Obstet Gynecol Int       Date:  2010-06-23

10.  In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.

Authors:  K El-Sahwi; S Bellone; E Cocco; M Cargnelutti; F Casagrande; M Bellone; M Abu-Khalaf; N Buza; F A Tavassoli; P Hui; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.